Form 4: Clive Meanwell Receives Stock Option Grant at Fractyl

Director Clive Meanwell was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Summary

• Clive Meanwell, a director at Fractyl Health, Inc. (GUTS), was awarded 22,500 stock options.
• The options have an exercise price of $0.7318 per share.
• The grant was issued on June 10, 2026, as part of the company's standard non-employee director compensation policy.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of the options.

Risks

• The value of the options is dependent on the future performance of the company's common stock.

Future Outlook

The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation in small-cap biotech firms.
• The vesting schedule is consistent with typical one-year cliff vesting structures used by peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Fractyl Health, GUTS, Director Compensation, Stock Options, Insider Transaction, Form 4